Announced Wed, 28 Oct, 2026 · 09:42 IST

Epigral to discuss Q2 FY27 results on November 2, 2026

Board & Shareholder Meetings View source PDF Explain this filing

EPIGRAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹897.50

prior close

₹892.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Specialty Chemicals peers, median of 99sector+0.2%+1.0% vs sector

On the reaction day the stock moved 1.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.8

15m

+0.7

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3pendingpending+0.2+1.0

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 99Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Epigral will hold a conference call at 5:00 PM IST on November 2, 2026, to discuss its second-quarter FY27 results. Chairman and Managing Director Maulik Patel, Executive Director Kaushal Soparkar, CFO Rakesh Agrawal, and investor relations head Milind Kotecha will participate. The filing also provides dial-in details.

Likely market impact

The call may help investors assess Q2 FY27 performance and management commentary, but the filing contains no financial figures or guidance.